HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis (Q24241472)

David W Johnson

6

0 references

Jonathan Craig

Jonathan C Craig

7

0 references

Giovanni Strippoli

8

Giovanni FM Strippoli

0 references

Sankar Navaneethan

1

Sankar D Navaneethan

0 references

Fabio Pellegrini

5

Fabio Pellegrini

0 references

author name string

Francesca Pansini

2

0 references

Carlo Manno

Cochrane Database of Systematic Reviews

4

0 references

publication date

15 April 2009

0 references

published in

0 references

cites work

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effect of pravastatin on proteinuria in patients with well-controlled hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effect of pravastatin on cardiovascular events in people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of r

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Impact of weight change on albuminuria in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vasc

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Safety and efficacy of atorvastatin in patients with severe renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Study of Heart and Renal Protection (SHARP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Prevalence of chronic kidney disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Meta-analysis: the effect of statins on albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effects of statins on inflammation in patients with acute and chronic coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Statins: effects beyond cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Statins for improving renal outcomes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Meta-analysis of biochemical and patient-level effects of calcimimetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

Cholesterol-lowering therapy may retard the progression of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Associated Effect of Hepatic Hydroxymethylglutaryl Coenzyme A Reductase + Angiotensin Converting Enzyme Inhibitors on the Progression of Renal Failure in Hypertensive Subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Predictors of Angiotensin-Converting Enzyme Inhibitor–Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784

7 January 2021

10.1002/14651858.CD007784

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

3510744

3510744

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference